VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2015.
Recent key clinical developments include:
•Reported new record high patient enrollment numbers - 24 patients in January, 25 patients in February and 29 patients in March in the Phase III head and neck cancer trial; with continued increase post-Q2 of 31 patients in April
Help employers find you! Check out all the jobs and post your resume.
